Biovest study backs non-Hodgkin

buluhofuce.wordpress.com
The study was featured at the ’sd annual meeting in Orlando, Biovest said in a release. It is a brighty spot for Biovest and itsparent company, (PINm SHEETS: ABPIQ), which filed for Chaptefr 11 bankruptcy late last year. BiovaxIDe is a personalized therapeutic anti-cancer vaccine individually manufactured from a tissue biopsy obtained froma patient’s own selectively targeting only the cancerous B-cells while sparing health cells. The study founds that patients who received BiovaxID experienced amedian disease-free survival of 44.2 month, comparerd to 30.6 months for those who receive a contro vaccine, an increase of 47 In follow-ups with a median of 4.
7 patients receiving BiovaxID experienced a 38 percent lowerf risk of disease recurrence compared to patients receiving the controll vaccine. BiovaxID is the first vaccine targeting lymphoma to demonstrate sucha disease-free survivalk benefit, the release said. Biovest (PINK SHEETS: has initiated discussions with the and the to determine the most appropriatreregulatory pathways, Samuel Duffey, president and generall counsel of Biovest, said in the release. The companyy also plans to make the vaccine available throughout most of Europe through a compassionate use drug accesw program that allows Europeanb physicians to prescribe drugs to qualifying patientsd before approvalsare granted.
Both Accentiaa (PINK SHEETS: ABPIQ), a drug development firm, and Bioves are headquartered in Tampa.